Search

Your search keyword '"Sarris, Andreas H."' showing total 14 results
Start Over Author "Sarris, Andreas H." Journal blood
14 results on '"Sarris, Andreas H."'

1. The Prognostic Significance of Serum Beta-2 Microglobulin (sβ2m) Levels in Patients with Hodgkin Lymphoma (HL): Final Analysis on 915 Patients Treated with ABVD or Equivalent (ABVDeq) Chemotherapy or Combined Modality Therapy (CT/CMT) Focusing to the Determination of Optimal Cut-Offs

Author

Vassilakopoulos, Theodoros P., primary, Arapaki, Maria Panagiota, additional, Diamantopoulos, Panagiotis T, additional, Angelopoulou, Maria K., additional, Nadali, Gianpaolo, additional, Tsourouflis, Gerasimos, additional, Moschogiannis, Maria, additional, Dimopoulou, Maria, additional, Siakantaris, Marina, additional, Yiakoumis, Xanthi, additional, Kontopidou, Flora, additional, Kalpadakis, Christina H., additional, Gainaru, Gabriela, additional, Asimakopoulos, John V., additional, Dimou, Maria, additional, Sachanas, Sotirios, additional, Kyrtsonis, Marie-Christine, additional, Tsaftaridis, Panayiotis, additional, Plata, Eleni, additional, Variami, Eleni, additional, Viniou, Nora-Athina, additional, Pizzolo, Giovanni, additional, Sarris, Andreas H., additional, Konstantopoulos, Kostas, additional, Panayiotidis, Panayiotis, additional, and Pangalis, Gerassimos, additional

Published
2022
Full Text
View/download PDF

2. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens

Author

Rassidakis, George Z., Medeiros, L. Jeffrey, Vassilakopoulos, Theodoros P., Viviani, Simonetta, Bonfante, Valeria, Nadali, Gianpaolo, Herling, Marco, Angelopoulou, Maria K., Giardini, Roberto, Chilosi, Marco, Kittas, Christos, McDonnell, Timothy J., Bonadonna, Gianni, Gianni, Alessandro M., Pizzolo, Giovanni, Pangalis, Gerassimos A., Cabanillas, Fernando, and Sarris, Andreas H.

Published
2002
Full Text
View/download PDF

4. Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo®) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas

Author

Hagemeister, Fredrick B., primary, Rodriguez, Maria Alma, additional, Deitcher, Steven R., additional, Younes, Anas, additional, Fayad, Luis, additional, Goy, Andre, additional, Dang, Nam H., additional, Forman, A, additional, McLaughlin, Peter, additional, Pro, Barbara, additional, Romaguera, Jorge Enrique, additional, Samaniego, Felipe, additional, Silverman, Jeffrey A., additional, Sarris, Andreas H., additional, and Cabanillas, Fernando, additional

Published
2013
Full Text
View/download PDF

5. Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

Author

Romaguera, Jorge Enrique, primary, Fayad, Luis, additional, Rodriguez, Maria Alma, additional, Hagemeister, F.B., additional, Pro, Barbara, additional, McLaughlin, Peter, additional, Younes, Anas, additional, Samaniego, Felipe, additional, Goy, Andre, additional, Sarris, Andreas H., additional, Dang, Nam H., additional, Wang, Luhua, additional, Kantarjian, Hagop M., additional, Beasley, Virginia, additional, Medeiros, L. Jeffrey, additional, Katz, Ruth L., additional, and Cabanillas, Fernando, additional

Published
2006
Full Text
View/download PDF

6. Primary Diffuse Large B-Cell Lymphoma of the Testis (PTL): A Prospective Study of Rituximab (R)-CHOP with CNS and Contralateral Testis Prophylaxis. Results of the IELSG 10 Study.

Author

Vitolo, Umberto, primary, Zucca, Emanuele, additional, Martelli, Maurizio, additional, Chiappella, Annalisa, additional, Baldi, Ileana, additional, Balzarotti, Monica, additional, Conconi, Annarita, additional, Gomez, Henry, additional, Lopez-Guillermo, Armando, additional, Martinelli, Giovanni, additional, Orsucci, Lorella, additional, Pavone, Vincenzo, additional, Rossi, Giuseppe, additional, Storti, Sergio, additional, Gospodarowicz, Mary K., additional, Cavalli, Franco, additional, and Sarris, Andreas H., additional

Published
2006
Full Text
View/download PDF

7. Prospective Management of Primary Testicular Lymphoma (PTL) with Doxorubicin-Based Chemotherapy, Prophylactic Intrathecal (IT) Methotrexate and Radiotherapy (RT), but without Rituximab: Results from IELSG.

Author

Sarris, Andreas H., primary, Vitolo, Umberto, additional, Zucca, Emanuele, additional, Rassidakis, George Z., additional, Medeiros, Jeffrey, additional, Cabras, Maria Giuseppina, additional, Di Rocco, Alice, additional, Pro, Barbara, additional, Gospodarowicz, Mary K., additional, and Cavalli, Franco, additional

Published
2006
Full Text
View/download PDF

8. Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS).

Author

Romaguera, Jorge Enrique, primary, Fayad, Luis, primary, Rodriguez, Maria A., primary, Hagemeister, Fredrick B., primary, Pro, Barbara, primary, McLaughlin, Peter, primary, Younes, Anas, primary, Samaniego, Felipe, primary, Goy, Andre, primary, Sarris, Andreas H., primary, Dang, Nam H., primary, Medeiros, L. Jeffrey, primary, Katz, Ruth, primary, Gagneja, Harish, primary, Samuels, Barry I., primary, and Cabanillas, Fernando, primary

Published
2004
Full Text
View/download PDF

9. The Clinical Significance of Molecular Response in Indolent Follicular Lymphomas

Author

López-Guillermo, Armando, primary, Cabanillas, Fernando, additional, McLaughlin, Peter, additional, Smith, Terry, additional, Hagemeister, Fredrick, additional, Rodrı́guez, Marı́a A., additional, Romaguera, Jorge E., additional, Younes, Anas, additional, Sarris, Andreas H., additional, Preti, H. Alejandro, additional, Pugh, William, additional, and Lee, Ming-Seng, additional

Published
1998
Full Text
View/download PDF

10. Correlation of Bcl-2Rearrangement With Clinical Characteristics and Outcome in Indolent Follicular Lymphoma

Author

López-Guillermo, Armando, Cabanillas, Fernando, McDonnell, Timothy I., McLaughlin, Peter, Smith, Terry, Pugh, William, Hagemeister, Fredrick, Rodríguez, M. Alma, Romaguera, Jorge E., Younes, Anas, Sarris, Andreas H., Preti, H. Alejandro, and Lee, Ming-Seng

Abstract

The t(14;18) translocation, which involves the bcl-2oncogene, occurs in follicular lymphomas (FL) at two common sites: the major breakpoint region (MBR) and the minor cluster region (mcr). The biological and clinical significance of these breakpoints is unknown. The bcl-2breakpoint site was determined in 247 previously untreated patients (49% men; median age 52 years) with indolent FL (155 grade I, 83 grade II, and 8 grade III) to correlate it with pretreatment characteristics, response, and outcome. The bcl-2breakpoint site was determined by a polymerase chain reaction method of peripheral blood (all cases), bone marrows (149 cases), and fresh lymph node biopsy specimens (68 cases). The breakpoint site occurred at MBRin 175 cases (71%) and atmcrin 27 (11%). In 45 cases (18%), no breakpoint was detected (germline). No significant relationship was found between the rearrangements and the expression of BLC-2and BAXproteins. Patients' germline for MBRand mcrtended to present more frequently with stage IV disease and higher β2-microglobulin (β2M) levels, whereas mcr-rearranged patients presented more frequently with early stage and normal β2M. The complete response rate of germline patients was significantly lower than that of MBRand mcrpatients. An estimated 3-year failure-free survival (FFS) for mcr, MBR, and germline cases was 95%, 76%, and 57%, respectively (P< .001). Thebcl-2breakpoint site was independent of serum β2M and lactate dehydrogenase in its correlation with FFS. In conclusion, thebcl-2rearrangement site is an important prognostic factor in indolent FL, useful to identify patients who may require different treatment.

Published
1999
Full Text
View/download PDF

11. Correlation of Bcl-2 Rearrangement With Clinical Characteristics and Outcome in Indolent Follicular Lymphoma

Author

Lo´pez-Guillermo, Armando, Cabanillas, Fernando, McDonnell, Timothy I., McLaughlin, Peter, Smith, Terry, Pugh, William, Hagemeister, Fredrick, Rodri´guez, M. Alma, Romaguera, Jorge E., Younes, Anas, Sarris, Andreas H., Preti, H. Alejandro, and Lee, Ming-Seng

Abstract

The t(14;18) translocation, which involves the bcl-2oncogene, occurs in follicular lymphomas (FL) at two common sites: the major breakpoint region (MBR) and the minor cluster region (mcr). The biological and clinical significance of these breakpoints is unknown. The bcl-2 breakpoint site was determined in 247 previously untreated patients (49% men; median age 52 years) with indolent FL (155 grade I, 83 grade II, and 8 grade III) to correlate it with pretreatment characteristics, response, and outcome. The bcl-2 breakpoint site was determined by a polymerase chain reaction method of peripheral blood (all cases), bone marrows (149 cases), and fresh lymph node biopsy specimens (68 cases). The breakpoint site occurred at MBR in 175 cases (71%) and atmcr in 27 (11%). In 45 cases (18%), no breakpoint was detected (germline). No significant relationship was found between the rearrangements and the expression of BLC-2 and BAXproteins. Patients’ germline for MBR and mcr tended to present more frequently with stage IV disease and higher ß2-microglobulin (ß2M) levels, whereas mcr-rearranged patients presented more frequently with early stage and normal ß2M. The complete response rate of germline patients was significantly lower than that of MBR and mcr patients. An estimated 3-year failure-free survival (FFS) for mcr, MBR, and germline cases was 95%, 76%, and 57%, respectively (P?

Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results